Data for: Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA)

Domain:

healthcare

Record type:

dataset

Creator:

KapOti

Editor:

Kap

The

Publisher:

Har

Host:

Malaria remains a major public health threat despite regulatory approval of a partially effective pre-erythrocytic malaria vaccine. There is an urgent need to accelerate the development of a more effective multi-stage vaccine. Controlled human malaria infection (CHMI) has been shown to be an important tool for the assessment of the efficacy of novel malaria vaccines and drugs prior to field trials. CHMI also allows for the evaluation of immunity to malaria and parasite growth rates in vivo. This is particularly useful in individuals from endemic areas with a level of exposure and immunity to malaria. Thus CHMI in individuals with prior exposure to malaria could be a valuable tool to accelerate malaria vaccine development. In this study, the investigators aim to use CHMI in semi-immune adults to provide a comprehensive prioritization of antigens associated with blood-stage immunity for vaccine development. The investigators will comprehensively characterize immunity to malaria using >100 antigens in up to 2,000 semi-immune adults, from known areas of malaria endemicity in Kenya, then select 200 individuals with a range of different immunological profiles, and conduct CHMI studies with serial quantitative polymerase chain reaction (PCR) to measure the parasite growth rate in vivo and relate this to host immunity.

The trial is registered at ClinicalTrials.gov: NCT02739763

Study Protocol: Controlled Human Malaria In…

Extended Data: Kapulu, Melissa C.; Njuguna…

Data Access: Restricted Access to these data requires submission of a formal request for consideration by our Data Governance Committee. How to request Download and complete the data request form Email completed data request form to the Data Governance Committee at dgc@kemri-wellcome.org License: Creative Commons Attribution 4.0 International

Visit

doi.org dataverse.harvard.edu

Licenses

info:eu-repo/semantics/restrictedAccess Custom terms specific to this dataset https://dataverse.harvard.edu/api/datasets/:persistentId/versions/3.0/customlicense?persistentId=doi:10.7910/DVN/YPVZFV

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): A study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity

Malaria remains a major public health burden despite approval for implementation of a partially effe

Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection

BACKGROUND Naturally acquired immunity to malaria is incompletely understood.

Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults

Identification and characterization of immunological responses induced by vaccination with R21/Matrix- M, using the controlled human malaria infection (CHMI) model in semi-immune adults.

Malaria remains a public health concern, and the development of a malaria vaccine remains a priority

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response

Abstract Background Individuals living in endemic areas acquire

Naturally acquired immunity among Kenyan adults suppresses the West African <i>P. falciparum</i> NF54 strain in controlled human malaria infection (CHMI)

Abstract We used controlled human malaria infection (CHMI) to s